Loading clinical trials...

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use | Clinical Trials | Clareo Health

RECRUITINGNA

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use

NCT06878859•Massachusetts General Hospital

Summary

The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged ≥ 18 years
•Resides in the United States
•Able to read and understand English and willing to provide informed consent/comply with the study protocol
•Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
•Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
•Current elevated anhedonia, as indicated by the PHQ-9
•Interest in receiving treatment for their cannabis use and depression
•Meet criteria for current MDD and CUD per the DSM-5

Exclusion Criteria

•History of a psychotic disorder or bipolar disorder type I/II
•Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
•Current psychotherapy engagement
•Changes in psychotropic medication within six weeks of the start of study

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

February 1, 2026

Primary Completion Date

January 1, 2028

Completion Date

January 1, 2029

Last Updated

February 27, 2026

Enrollment

ESTIMATED participants

Conditions

Depression - Major Depressive DisorderCannabis Use DisorderMental Disorder

Interventions

Amplification of Positivity - Cannabis Use (AMP-C)

BEHAVIORAL

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

NCT01778504

Neuropsychiatric DisorderNeurological Disorder+2 more

View study

RECRUITING

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

NCT06690151

Heart Disease CongenitalNeurodevelopmental Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Inclusion Criteria

Exclusion Criteria

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Psychiatric Multi-omics and Neuroimaging Project

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)